Document is current

Article History

Received: 12 May 2025

Accepted: 18 March 2026

First Online: 27 March 2026

Declarations

:

: Ethics approval and consent: This study obtained ethics approval from the Institutional Review Board (IRB) of Texas Tech Health Sciences Center El Paso; study number E24053 was designated as exempt under Category 2 of 45 CFR 46.104(d), which covers research involving educational tests, survey procedures, interview procedures, or observation of public behavior. Prior to completing the survey, participants were provided a brief information statement describing the purpose of the project, what participation involved (completion of an anonymous survey taking approximately 5 min), that no identifiable information would be collected, and that they could decline to answer any question without penalty. Informed consent was obtained from participants as implied consent, with completion and return of the anonymous survey indicating consent to participate. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.

: Not Applicable.

: A.G is a board-certified dermatologist in El Paso, Texas who is affiliated with several hospitals, including Las Palmas Medical Center and The Hospitals of Providence. He is also a fellow of the AAD, the American Society for Mohs Surgery, and the American Society for Dermatologic Surgery. N.B. and T.T. serve on the board of directors for the Colorado Melanoma Foundation. N.B. also serves as Co-Chair, Skin Cancer Task Force for the Colorado Cancer Coalition Board of Directors. J.C. serves as a consultant and Immunotherapy Subject Matter Expert for Guidepoint Consulting (New York, NY) and is co-inventor on Patent Number(s): US20170044496A1 and received royalties for this technology license. No other authors claim any conflict of interest.